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Myeloid sarcoma of the cheek and the maxillary sinus regions
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Received September 16, 2011; accepted December 7, 2011AbstractMyeloid sarcoma (MS) is a rare, extramedullary malignant tumor composed of immature myeloid precursor cells and myeloblast. Most MSs
occur in the subperiosteal region of the bone, with the skull, sternum, ribs, and proximal portions of the long bones being the common sites of
involvement. It is thought that the MS tumor originates in the bone marrow, and traverses the Haversian canals to reach the subperiosteum.
Various reports have also described the involvement of the liver, spleen, brain, heart, pharynx, uterus, vagina, skin, kidney, and other soft tissues
in the formation of the tumor.
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Although myeloid sarcomas (MSs) are not commonly
found in the oral cavity, the formation of such tumors can
involve the palate, gingiva, and cheek. Herein, we present
a report of MS without hematological disorders, and discuss
our experience with this specific clinical finding as well as our
surgical approach.
2. Case report
A 56-year-old man suffered from a swelling (lesion) in the
left cheek with a noticeable mass for months. This cheek
lesion slowly enlarged over the months and a mild tenderness
was reported. He visited an oral surgery department, where
a physical examination was performed, which revealed a soft
and solid mass, measuring 4 cm in diameter on the left
cheek.
The hematocrit level of the patient was 48%, and his white
blood cell count was 9500/mm3 with 13.5% lymphocytes and* Corresponding author. Dr. Shih-Lun Chang, Department of the Otolar-
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treatment involved incision and drainage as well as admin-
istration of oral antibiotics; however, the swelling did not
subside following the treatment. Therefore, a pathological
analysis was conducted, which revealed a granulation tissue
without malignancy, prompting a referral to the laryngological
service for further evaluation. A computed tomography scan
was performed, which revealed an enhancing soft tissue mass
(diameter: 4.2  4.0  3.7 cm) involving the left cheek and
the left maxillary sinus region. The differential diagnosis
could be an immature abscess, a lymphoma, and several other
types of tumors (Fig. 1). After having a discussion with the
patient, we performed an operation to remove the lesion on the
left cheek and the left maxillary sinus region, by following the
CaldwelleLuc surgical procedure. A tissue proofing was
carried out, which revealed that the specimen was composed
of brown tissues diffusely infiltrating the left cheek without
epithelial rupture and measuring up to 3  2.5  1.2 cm.
Further examination of the tissue sections showed diffuse
infiltration of tumor cells in the fibroadipose tissue and skel-
etal muscle fibers. The tumor cells were medium sized, with
oval and vesicular nuclei, open chromatin pattern, and some
with a prominent nucleolus. At higher magnification levels,
the tumor cells exhibited a high nuclear-to-cytoplasmic ratio,
with round- to ovoid-shaped nuclei.hinese Medical Association. All rights reserved.
Fig. 1. (A) Enhancing soft tissue (diameter of 4.2  4.0  3.7 cm) involving the left cheek and the left maxillary sinus region. (B) The cheek lesion completely
regressed after therapy.
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plastic cells were positive for CD34, CD45, CD56, CD117,
and myeloperoxidase (MPO), but not for CD3, CD4, CD20,
CD30, CD68, terminal deoxynucleotidyl transferase (TdT),
vimentin, or cytokeratin AE1/AE3 (Fig. 2). The results of
these diagnostic tests and examination suggested MS. The
patient was subsequently referred for a hematological workup,
in order to exclude other synchronous myeloproliferative
disorders. No alterations in the peripheral blood profile were
noted, and the results of his bone marrow biopsy showed
normocellular marrow without malignancy. Immunohis-
tochemical staining with anti-CD34 showed scant positive
cells. No CD117-positive cells were identified, excluding
acute myeloid leukemia. On the basis of the composite clin-
icopathological data, the patient accepted combination che-
motherapy of low-dose cytarabine (arabinofuranosyl cytidine)
(20 mg/day subcutaneously, on days 1e25) and aclarubicin
(10 mg/day intravenously, on days 1e4). Four months after
admission, the cheek lesion had completely regressed and the
patient was in clinical and hematologic remission (Fig. 1). We
did not supplement the course of treatment with radiation
therapy because the disease did not persist after the combi-
nation chemotherapy was completed.3. Discussion
MS is a localized, solid, extramedullary tumor composed of
immature myeloid precursor cells. Burns1 first described
a patient with proptosis and green retro-orbital tumors in 1823,
and Dock2 later established the relationship of MS with acute
leukemia. Turk et al3 reported the first case of myelocytic
leukemia associated with chloroma. Almost all cases of
chloroma reported since then have been shown to be asso-
ciated with myelocytic or monocytic leukemia. The MS tumor
is more common in children and young adults.4 A vast ma-
jority of MSs occur in the subperiosteal region of the bone,
with the skull, sternum, ribs, and the proximal portions of long
bones being common sites of involvement.5 MS is defined as
a tumor mass of myeloid blasts with or without maturation
occurring at an anatomical site other than the bone marrow,
with normal architectural effacement. It is particularly
important to identify any destructive growth to characterize
the lesion to be MS in patients with leukemia.
The existing literature suggests that the tumor arises from
the bone marrow, and traverses the Haversian canals to reach
the subperiosteum.5 In our case, the tumor (lesion
4.2  4.0  3.7 cm) occurred on the left cheek and the left
Fig. 2. (A) Medium to large-sized blastic cells with ovoid vesicular nuclei with
medium or large centrally located nucleoli and dispersed chromatin. Their
cytoplasm is scant to moderate and the mitotic count is high (hematoxylin and
eosin, 400). (B) Neoplastic cells are positive for CD68.
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elevated after incision, and upon finding the suspected mass
lesion, we determined that the maxilla bone was complete and
intact, without any obvious bony disruption. Examples of MS
unrelated to the bone are very infrequently noted in the
medical literature, making it very difficult to diagnose.
Therefore, the diagnosis of the tumor solely relies upon
a radiological finding. The tumor appears green in white light,
and fluoresce red when exposed to ultraviolet light.5 Schultz
and Rosenthal found that crystalline myeloperoxidase has
a green color and illuminates red under ultraviolet light.6 They
identified the fluorescent material as porphyrins, and postu-
lated that myeloperoxidase may be derived from a porphyrin
protein complex. This enzyme has a molecular weight of about
160,000 and catalyzes the oxidation of amino acids by
hydrogen peroxide. A greenish coloration of the bone marrow
in an otherwise typical case of acute myelocytic leukemia may
be a more common presentation of chloroma than discrete
tumor formation.7 Typical distinctive pigmentation is reduced,
and therefore, the term granulocytic sarcoma is more appro-
priate than chloroma. Usually, acute leukemia and chloroma
are diagnosed simultaneously. It is rare that MS precedes acute
leukemia by less than 1 month to over a year.MS is usually composed of relatively uniform, primitive cells
that may be peroxidase positive or negative. Rappaport et al9
maintains that a definite diagnosis must be based on the iden-
tification of such cells in the blood and marrow. The diagnosis
becomes difficult when nonpigmented MS precedes acute leu-
kemia. One form of the disease, reticulum cell sarcoma, occurs
primarily as a single or multiple solid tumors. Another more
malignant form of the disease, acute myelocytic or monocytic
leukemia, commonly occurs as a widespread infiltrative ma-
lignancy without discrete tumor formation. An intermediate
between these two extremes may be an MS, a phase of wide-
spread solid tumors. The use of only four antibodies (MPO,
CD68, lysozyme, and CD34) has been proposed to distinguish
the more common variants of MSs. A study of 30 cases showed
CD117 reactivity in 87%, MPO, 97%; lysozyme, 93%; CD34,
47%; CD45, 84%; CD43, 97%; TdT, 37%; CD79a, 20%; CD20,
10%; CD3, 10%; and CD10, 1%. There is no standard treatment
for MS, especially when it occurs de novo9; rather, treatment is
similar to that of a systemic disease, as it is considered to be
a manifestation of such diseases. When a patient with MS has
leukemia or relapsed leukemia, combination chemotherapy for
acute leukemia may induce complete remission. Additional
radiation therapy is often considered when the disease persists
after chemotherapy. Systemic chemotherapy also may induce
complete remission in the patient with de novo MS.10
The prognosis of MS is generally unfavorable. Pileri et al8
reported that of the 67 patients for whom follow-up data were
available, 60 died from the disease (89.5%). Interestingly, all
the seven survivors achieved complete remission of their MS
following first-line therapy, in contrast to only eight of the 60
patients who died achieved complete remission. Bone marrow
transplantation resulted in longer survival than conventional
therapy. Based on these results, the authors strongly recom-
mended that patients with MS should undergo high-dose ther-
apies as a front-line approach, noting that this appeared to be the
only chance to achieve complete remission and to cure the
disease. Even though the prognosis ofMS is very poor, it should
be diagnosed as early as possible because early high-dose
therapies offer the only possibility of cure. Finally, in patients
with leukemia, even in those in complete remission, physicians
should not overlook symptoms mimicking facial cellulitis or
abscess and must bear in mind the possibility of MS.
We present this case of specific radiological finding and
surgical approach to MS of the cheek and maxillary sinus. The
disease is often easily misdiagnosed, so we recommended all
cases of head and neck tumor refractory to medical treatment be
treated with aggressive surgical approach for complete tissue
proof.
In conclusion, it is remarkable that in clinical practice there is
frequent misdiagnosis of MS. Histological analyses show that
MS has an abundance of monomorphic polyhedral cells with
irregular nuclear contours. Immunohistochemical studies may
help in reaching a definitive diagnosis because myeloid cells are
reactive to antibodies against lysozyme, myeloperoxidase, and
chloroacetate esterase. In addition, flow cytometry and cyto-
genetics may help to improve the likelihood of a correct,
definitive diagnosis. Imaging studies can also be useful to rule
238 K.-D. Mei et al. / Journal of the Chinese Medical Association 76 (2013) 235e238out inflammatory lesions. Further clinical hematological in-
vestigations, including a bone marrow biopsy, are therefore
recommended in each case of MS. MS of the head and neck
carries prognostic significancewith blast crisis, so an aggressive
surgical approach for complete tissue proof is suggested for
recurrent lesions that are refractory to medical treatment.
Complete excision of tumor with a satisfactory free margin can
more effectively create the foundation for a reliable and accurate
diagnosis for suspected malignancy, and better differentiate it
from infection etiology.
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